Supernus Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio27.031201.4231.7629.0310.44
Forward P/E19.6515.3430.8415.7315.72
P/S Ratio3.022.602.892.672.55
P/B Ratio1.931.722.181.901.78
Price/Tangible Book5.037.7328.904.38
Price/FCF11.6614.3016.5612.409.84
Price/OCF11.6114.2316.5012.209.58
PEG Ratio1.111.111.111.111.11
Enterprise Value Ratios
EV/Revenue2.462.302.771.951.96
EV/EBITDA11.5114.2314.1010.065.26
EV/EBIT26.59104.3140.5314.185.80
EV/FCF9.5312.6515.889.017.56
Profitability & Returns
Return on Equity (ROE)0.08%0.00%0.07%0.07%0.19%
Return on Assets (ROA)0.03%0.01%0.02%0.03%0.08%
Return on Invested Capital (ROIC)0.07%0.01%0.05%0.07%0.19%
Return on Capital Employed (ROCE)0.06%0.01%0.04%0.06%0.14%
Leverage & Solvency Ratios
Debt/Equity0.030.040.510.540.59
Debt/EBITDA0.220.373.133.552.17
Debt/FCF0.200.383.873.523.24
Liquidity Ratios
Current Ratio2.351.701.071.912.57
Quick Ratio2.041.380.911.552.30
Efficiency Ratios
Asset Turnover0.500.410.390.360.39
Inventory Turnover1.180.990.981.121.40
Yield & Distribution Ratios
Earnings Yield0.04%0.00%0.03%0.03%0.10%
FCF Yield0.09%0.07%0.06%0.08%0.10%
Buyback Yield-0.01%0.10%-0.13%-0.01%0.00%